ARS Pharmaceuticals, Inc (SPRY) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of ARS Pharmaceuticals, Inc stock $3.00, price $3.59, that is 16.4% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
ARS Pharmaceuticals, Inc
SPRY · USExpensive (fair value 16% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $2.65 – $30.91 · fair‑value band $2.25 – $3.76 · the $3.59 price screens above the $3.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether ARS Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
Show moreShow less
The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Stock analysis
ARS Pharmaceuticals, Inc (SPRY) currently trades at $3.59, while our estimate is $3.00, 16% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $2.25 (bear) to $3.76 (bull), the price of $3.59 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
ARS Pharmaceuticals, Inc reported revenue of $84.3M in FY2025 versus $5.5M in FY2021, a compound +97.8%/yr. Reported net income was −$171M in FY2025.
Key figures
Market cap $357M Small · P/S ratio 2.30 · EPS (TTM) $−2.01 · Return on equity −295% · Return on assets (EBIT) −25.8% (5-year average) · Operating margin −90.6% · Revenue (TTM) $122M · Revenue growth (YoY) +16.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 73% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, SPRY screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 2 officers or directors sold shares worth $283,550 and none bought.
- SaleAlexander A FitzpatrickChief Legal Officer3,355 shares at $10.00$33,550Jun 12, 202610b5-1 plan
- SaleEric KarasChief Commercial Officer25,000 shares at $10.00$250,000Jun 12, 202610b5-1 plan
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...
- ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
- ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
Compare ARS Pharmaceuticals, Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs SPRY |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs SPRY |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs SPRY |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs SPRY |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs SPRY |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs SPRY |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs SPRY |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs SPRY |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs SPRY |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs SPRY |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is ARS Pharmaceuticals, Inc (SPRY) overvalued or undervalued?
What is the fair value of SPRY?
What is the quality score of SPRY?
What is the price target for ARS Pharmaceuticals, Inc (SPRY)?
What is the ARS Pharmaceuticals, Inc stock forecast for 2026?
What is the revenue of ARS Pharmaceuticals, Inc (SPRY)?
What is the intrinsic value of ARS Pharmaceuticals, Inc (SPRY)?
Is ARS Pharmaceuticals, Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SPRY?
How much is ARS Pharmaceuticals, Inc worth?
What do the bullish and bearish scenarios say about SPRY?
How solid is the balance sheet of ARS Pharmaceuticals, Inc (SPRY)?
How far is SPRY from its 52-week high?
Which stocks are comparable to ARS Pharmaceuticals, Inc?
Is ARS Pharmaceuticals, Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of ARS Pharmaceuticals, Inc (SPRY)?
What should I pay attention to with ARS Pharmaceuticals, Inc right now?
Key figures of ARS Pharmaceuticals, Inc
How large is the market capitalisation of ARS Pharmaceuticals, Inc (SPRY)?
What is the P/S ratio of ARS Pharmaceuticals, Inc (SPRY)?
What are the earnings per share of ARS Pharmaceuticals, Inc (SPRY)?
What is the return on equity of ARS Pharmaceuticals, Inc (SPRY)?
What is the EBIT return on assets of ARS Pharmaceuticals, Inc (SPRY)?
What is the operating margin of ARS Pharmaceuticals, Inc (SPRY)?
How fast is revenue growing at ARS Pharmaceuticals, Inc (SPRY)?
How much free cash flow does ARS Pharmaceuticals, Inc (SPRY) generate?
How much net debt does ARS Pharmaceuticals, Inc (SPRY) carry?
Watch ARS Pharmaceuticals, Inc in the live analysis
One click puts ARS Pharmaceuticals, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.